AU2002223599A1 - Pyrimidinone derivatives and their use in the treatment of atherosclerosis - Google Patents
Pyrimidinone derivatives and their use in the treatment of atherosclerosisInfo
- Publication number
- AU2002223599A1 AU2002223599A1 AU2002223599A AU2359902A AU2002223599A1 AU 2002223599 A1 AU2002223599 A1 AU 2002223599A1 AU 2002223599 A AU2002223599 A AU 2002223599A AU 2359902 A AU2359902 A AU 2359902A AU 2002223599 A1 AU2002223599 A1 AU 2002223599A1
- Authority
- AU
- Australia
- Prior art keywords
- atherosclerosis
- treatment
- pyrimidinone derivatives
- pyrimidinone
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0024807 | 2000-10-10 | ||
GBGB0024807.0A GB0024807D0 (en) | 2000-10-10 | 2000-10-10 | Novel compounds |
PCT/EP2001/011562 WO2002030911A1 (en) | 2000-10-10 | 2001-10-05 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002223599A1 true AU2002223599A1 (en) | 2002-04-22 |
Family
ID=9901005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002223599A Abandoned AU2002223599A1 (en) | 2000-10-10 | 2001-10-05 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis |
Country Status (11)
Country | Link |
---|---|
US (2) | US7169924B2 (en) |
EP (1) | EP1337517B1 (en) |
JP (1) | JP2004511473A (en) |
AR (1) | AR035068A1 (en) |
AT (1) | ATE415392T1 (en) |
AU (1) | AU2002223599A1 (en) |
CA (1) | CA2459746A1 (en) |
DE (1) | DE60136736D1 (en) |
ES (1) | ES2317949T3 (en) |
GB (1) | GB0024807D0 (en) |
WO (1) | WO2002030911A1 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060805A1 (en) * | 2000-02-16 | 2001-08-23 | Smithkline Beecham P.L.C. | Pyrimidine-4-one derivatives as ldl-pla2 inhibitors |
GB0024807D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
GB0119793D0 (en) * | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
GB0127139D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0127140D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0208280D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
GB0208279D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
EP1735457A4 (en) | 2004-04-16 | 2007-08-29 | Glaxo Group Ltd | METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY |
US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
CN101341128A (en) * | 2005-12-23 | 2009-01-07 | 阿斯利康(瑞典)有限公司 | Pyrazoles for the treatment of gerd and ibs |
US20080090851A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
US7705005B2 (en) * | 2006-10-13 | 2010-04-27 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
US20080090852A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
WO2008048867A2 (en) * | 2006-10-13 | 2008-04-24 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
KR101461659B1 (en) | 2007-05-11 | 2014-11-17 | 토마스 제퍼슨 유니버시티 | Methods of treatment and prevention of neurodegenerative diseases and disorders |
WO2008141176A1 (en) * | 2007-05-11 | 2008-11-20 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
KR101931628B1 (en) | 2010-06-18 | 2019-03-13 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Pla2g16 as a target for antiviral compounds |
JP5886310B2 (en) | 2010-12-06 | 2016-03-16 | グラクソ グループ リミテッドGlaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 |
EP2651403B1 (en) | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases |
WO2012129792A1 (en) * | 2011-03-30 | 2012-10-04 | 中国科学院上海药物研究所 | Pyrimidinone compounds, preparation methods, pharmaceutical compositions and uses thereof |
CN103619831B (en) | 2011-06-27 | 2016-05-04 | 中国科学院上海药物研究所 | Azole heterocyclic compound, its preparation method, pharmaceutical composition and purposes |
RU2014107486A (en) | 2011-07-27 | 2015-09-10 | Глэксо Груп Лимитед | Bicyclic pyrimidone compounds |
BR112014001665A2 (en) | 2011-07-27 | 2017-02-14 | Glaxo Group Ltd | 2,3-dihydroimidazo [1,2-c] pyrimidin-5 (1h) -one compounds used as lp-plaz inhibitors |
FR2994184B1 (en) | 2012-08-02 | 2017-12-08 | Biomerieux Sa | METHODS OF FUNCTIONALIZATION AND REAGENTS USED IN SUCH METHODS USING AN AZA-ISATOIC ANHYDRIDE OR ONE OF ITS DERIVATIVES, BIOLOGIC MOLECULES SO TREATED AND KITS |
JP2016505053A (en) | 2013-01-25 | 2016-02-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2 |
UY35276A (en) | 2013-01-25 | 2014-08-29 | Glaxosmithkline Ip Dev Ltd | New compounds that inhibit the activity of Lp-PLA2 |
WO2014114248A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2016198691A1 (en) | 2015-06-11 | 2016-12-15 | Basilea Pharmaceutica Ag | Efflux-pump inhibitors and therapeutic uses thereof |
CN111825695B (en) * | 2019-04-15 | 2022-04-12 | 中国科学院上海药物研究所 | Oxazolidinone compound, preparation method, application and pharmaceutical composition thereof |
US11591840B1 (en) * | 2019-10-31 | 2023-02-28 | Andersen Corporation | Power window operators, windows and methods |
CN112778331B (en) | 2019-11-09 | 2022-07-05 | 上海赛默罗生物科技有限公司 | Tricyclic dihydroimidazopyrimidinone derivatives, preparation method, pharmaceutical composition and application thereof |
CN115304620A (en) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | Pyrimidone derivatives, preparation method, pharmaceutical composition and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001522844A (en) * | 1997-11-06 | 2001-11-20 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Pyrimidinone compounds and pharmaceutical compositions containing them |
WO2001060805A1 (en) * | 2000-02-16 | 2001-08-23 | Smithkline Beecham P.L.C. | Pyrimidine-4-one derivatives as ldl-pla2 inhibitors |
GB0024807D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
US6649610B1 (en) * | 2001-05-23 | 2003-11-18 | University Of Central Florida | 2-oxo-1, 4-benzoxazine compounds for treatment of tuberculosis |
-
2000
- 2000-10-10 GB GBGB0024807.0A patent/GB0024807D0/en not_active Ceased
-
2001
- 2001-10-05 ES ES01986682T patent/ES2317949T3/en not_active Expired - Lifetime
- 2001-10-05 WO PCT/EP2001/011562 patent/WO2002030911A1/en active Application Filing
- 2001-10-05 AU AU2002223599A patent/AU2002223599A1/en not_active Abandoned
- 2001-10-05 AT AT01986682T patent/ATE415392T1/en not_active IP Right Cessation
- 2001-10-05 US US10/398,977 patent/US7169924B2/en not_active Expired - Fee Related
- 2001-10-05 CA CA002459746A patent/CA2459746A1/en not_active Abandoned
- 2001-10-05 DE DE60136736T patent/DE60136736D1/en not_active Expired - Lifetime
- 2001-10-05 JP JP2002534297A patent/JP2004511473A/en active Pending
- 2001-10-05 EP EP01986682A patent/EP1337517B1/en not_active Expired - Lifetime
- 2001-10-10 AR ARP010104761A patent/AR035068A1/en unknown
-
2006
- 2006-07-07 US US11/456,129 patent/US7462620B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
GB0024807D0 (en) | 2000-11-22 |
EP1337517A1 (en) | 2003-08-27 |
ES2317949T3 (en) | 2009-05-01 |
US20060241126A1 (en) | 2006-10-26 |
AR035068A1 (en) | 2004-04-14 |
CA2459746A1 (en) | 2002-04-18 |
ATE415392T1 (en) | 2008-12-15 |
JP2004511473A (en) | 2004-04-15 |
US7169924B2 (en) | 2007-01-30 |
US20040058941A1 (en) | 2004-03-25 |
EP1337517B1 (en) | 2008-11-26 |
WO2002030911A1 (en) | 2002-04-18 |
DE60136736D1 (en) | 2009-01-08 |
US7462620B2 (en) | 2008-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002223599A1 (en) | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | |
AU2002225356A1 (en) | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | |
AU2001293553A1 (en) | Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment | |
AU4171500A (en) | Flupirtine in the treatment of fibromyalgia and related conditions | |
AU4289100A (en) | Dihydropyrimidines and their use in the treatment of hepatitis | |
IL185461A0 (en) | Pyrimidine compounds and their use | |
AU2002225954A1 (en) | Dipeptidylpeptidases and methods of use | |
PL352330A1 (en) | Derivatives of pyridopyranoazepine, making of same and use of same in therapy | |
AU2001281850A1 (en) | Use of inulin and inulin derivatives | |
AU2001264258A1 (en) | Nonwoven-fabric laminate and use thereof | |
AU2001283285A1 (en) | Antimicrobial composition and methods of use in the treatment of disease | |
AU2002247208A1 (en) | Selective pde3b inhibitors and use of the same in therapy | |
AU2002211717A1 (en) | Stresscopins and their uses | |
AU2001272011A1 (en) | Siderophores-producing bifidobacteria thereby and uses thereof | |
HU0001396D0 (en) | 3-amino-3-arylpropan-1-al derivatives and their use | |
AU2002213346A1 (en) | Osteopontin-coated surfaces and methods of use | |
AU2002343103A1 (en) | Aminoalkylimidazole derivatives and their use in medicine | |
AU2002243363A1 (en) | Use of aziridino-compounds in the treatment of immune dysfunctions | |
AU7458201A (en) | Laminate and use thereof | |
AU2001261750A1 (en) | Laminate and its use | |
AU2001262149A1 (en) | 2-(indanylamino)pyrimidone and 2-(tetrahydronaphthalenylamino)pyrimidone derivatives | |
AU2001252132A1 (en) | Substituted 5-methyldihydropyridazinones and their use in the prophylaxis and/ortreatment of anemias | |
AU2001261375A1 (en) | Human caspase-12 materials and methods | |
AU4129800A (en) | Bis-benzazoles and their use as antineoplastic agents | |
AU2001241195A1 (en) | Pyrimidinone derivatives and herbicides |